Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 932,725 shares, an increase of 1,541.9% from the September 15th total of 56,809 shares. Based on an average daily volume of 6,278,931 shares, the days-to-cover ratio is presently 0.1 days. Currently, 11.6% of the company’s stock are short sold.
Evogene Price Performance
Shares of EVGN stock traded down $0.02 during trading hours on Friday, reaching $0.38. The company had a trading volume of 105,888 shares, compared to its average volume of 1,171,209. The company has a market cap of $3.33 million, a price-to-earnings ratio of -0.42 and a beta of 1.44. Evogene has a 12 month low of $0.35 and a 12 month high of $1.49. The business has a fifty day simple moving average of $0.52 and a 200-day simple moving average of $0.61.
Insider Buying and Selling
In other Evogene news, Director Leon Recanati purchased 460,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the purchase, the director owned 1,343,886 shares of the company’s stock, valued at $860,087.04. This trade represents a 52.04% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 7.40% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Analysis on EVGN
About Evogene
Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.
Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.
See Also
- Five stocks we like better than Evogene
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
